New Phase 3 trial: A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time — Pfizer
Why now
Thesis: Durability data needed before COPD launch case
Catalyst to watch: Long-term safety and exacerbation-rate results
Main risk: Chronic dosing safety signals could derail program
Why it matters
Long-term extension study for Pfizer's tilrekimig in COPD addresses durability, a key gating factor for chronic respiratory biologics.
Details
Sponsor: Pfizer; Status: Not Yet Recruiting; Conditions: Moderate to Severe Chronic Obstructive Pulmonary Disease; Interventions: Tilrekimig; Enrollment: 1360 (estimated); First posted: 2026-09-24; NCT: NCT07839884
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-24 12:00 UTC